Human Normal Immunoglobulins Pharma Grade API is a polyvalent human plasma-derived immunoglobulin G fraction supplied under two model designations: HNI-P-API-Oral, a spray-dried or lyophilized powder for tablet, capsule, granule, and oral solution processes, and HNI-P-API-Injectable, a sterile-filtered liquid or lyophilized intermediate for intramuscular, subcutaneous, and intravenous formulation after appropriate dilution. The API is separated from pooled human plasma by cold ethanol fractionation using Cohn–Oncley conditions at −5 °C to 8 °C, followed by caprylate precipitation or anion-exchange chromatography for injectable grades. Virus reduction is achieved by at least two orthogonal steps, typically solvent/detergent treatment with tri-n-butyl phosphate and polysorbate 80 and 20 nm nanofiltration, with process validation performed against enveloped and non-enveloped model viruses. Injectable-grade material is controlled under Ph. Eur. 0918 and EU GMP Annex 1 requirements, while oral-grade material is manufactured under general pharmaceutical-grade conditions but is not terminally sterilized. The oral-grade powder is dispensed with a defined particle-size specification D90 ≤ 180 µm, and the injectable-grade liquid intermediate is sterile-filtered through 0.2 µm membranes prior to filling. The finished injectable liquid typically contains glycine at 0.15–0.20 M and polysorbate 80 at ≤ 100 ppm; the oral powder contains trehalose or mannitol as a lyoprotectant and does not require a preservative.

Ethanol fractionation uses 25% ethanol at −5 °C to precipitate fibrinogen and factor VIII; the IgG-enriched fraction II/III is redissolved and subjected to caprylate at pH 4.8 to remove IgA, IgM, and residual lipids. Diafiltration against 10 mM sodium phosphate at pH 5.5 reduces ionic strength before ion-exchange chromatography. The injectable-grade eluate is nanofiltered, concentrated to 100–180 g/L, and formulated with glycine at 0.15–0.20 M. The oral-grade powder is spray-dried or lyophilized from a similar intermediate but is not subjected to terminal sterilization.

What Are the Release Specifications for the Oral and Injectable Grades?

Release testing uses the same pharmacopoeial test methods but applies different action limits to the two model designations. The oral grade permits a higher bioburden because downstream solid-dosage processing does not guarantee sterility, whereas the injectable grade must meet sterility and pyrogen limits prior to final filling. Total IgG purity is expressed as a percentage of total protein by agarose gel electrophoresis or capillary zone electrophoresis; both grades are released with IgG ≥ 95% of total protein. Molecular size distribution is determined by size-exclusion HPLC using a phosphate-saline mobile phase at pH 7.4; injectable-grade monomer and dimer content is controlled at ≥ 90%, while oral-grade aggregation limits may be widened if formulation studies confirm equivalence. Residual IgA is controlled in intravenous-grade material because IgA-deficient recipients may develop antibodies to IgA; the common acceptance limit for intravenous administration is ≤ 0.14 mg/mL, but the limit is product-specific and relies on anti-complementary activity and prekallikrein activator data. Anticomplementary activity for the injectable grade is limited to ≤ 1 CH50/mg of protein; the oral grade is not routinely tested because it is not infused intravenously. Prekallikrein activator is controlled at ≤ 35 IU/mL for intravenous-grade liquid. Osmolality of the ready-to-infuse liquid is adjusted to 250–350 mOsmol/kg; intramuscular and subcutaneous formulations may have higher osmolality but must remain below 500 mOsmol/kg to limit injection pain.

Viral marker testing is performed on every plasma pool by nucleic acid amplification: hepatitis B surface antigen, anti-HIV-1/2, anti-HCV, and HCV RNA are negative prior to fractionation. Parvovirus B19 DNA loads in pooled plasma are limited by NAT, but the acceptance value is product-specific and harmonized between plasma fractionators; published pharmacopoeial numeric limits for this specific configuration are limited.

Powder Properties Governing Tablet, Capsule, and Granule Processing

During dry granulation and tableting of the oral-grade API, the powder exhibits cohesive flow at moisture contents above 3.5%; slugging or roller compaction is therefore preferred over wet granulation unless a hydroalcoholic binder is used. The API's glass transition temperature at 40% RH is commonly in the range 68–74 °C, and drying above this range should be avoided to prevent particle fusion and loss of Fab-dependent antigen-binding activity. For capsule filling on dosator-type machines, the powder may require addition of 0.5–1.0% fumed silica or magnesium stearate as a flow aid, but excessive hydrophobic lubricant can delay disintegration beyond 30 min and reduce IgG release in 0.1 M HCl. A tablet formulation containing 10% croscarmellose sodium and 5% silicified microcrystalline cellulose is evaluated against USP <711> dissolution requirements; published data for this specific composition is limited, and each formulation must be confirmed by multivariate stability studies. The oral-grade material should be stored at 2–8 °C in sealed double polyethylene bags with desiccant; if exposed to RH > 60%, pre-drying is required before tablet compression. Enteric-coated capsules or gastro-resistant granules are necessary for oral use because IgG is acid-labile and denatures at gastric pH 1.2. Enteric coating is applied as a methacrylic acid copolymer film with a dissolution threshold at pH > 5.5 to protect IgG from gastric acid; in vitro release is assessed in 0.1 M HCl for 2 h followed by pH 6.8 phosphate buffer.

The oral API particle size is controlled by laser diffraction; D10 ≤ 30 µm, D50 ≤ 80 µm, D90 ≤ 180 µm. Clinical evidence for enteric protection in necrotizing enterocolitis and rotavirus infection remains product-specific, and efficacy is not inferred from serum immunoglobulin studies. The oral product acts topically in the gastrointestinal tract and is not a substitute for injectable immunoglobulin replacement therapy.

When Injectable-Grade Material Is Subjected to Viral Clearance and Sterile Filtration

Liquid injectable-grade material must achieve a viral reduction capacity of at least 4 log10 for enveloped viruses and at least 4 log10 for non-enveloped model viruses across the production steps. Solvent/detergent treatment with tri-n-butyl phosphate and polysorbate 80 is effective against enveloped viruses but has no activity against parvovirus B19; therefore a 20 nm nanofiltration step follows. The sterile filtration train uses a 0.2 µm membrane with integrity testing by bubble point or diffusive flow before and after filling. Liquid formulations are tested for subvisible particulates by light obscuration per Ph. Eur. 2.9.19 and USP <788>; acceptance is ≤ 6,000 particles per container ≥ 10 µm and ≤ 600 particles per container ≥ 25 µm for containers up to 100 mL. Intravenous infusion rate begins at 0.5 mg/kg/min and may be increased to 6 mg/kg/min if tolerated; dosing for primary immunodeficiency is commonly 400–600 mg/kg every 3–4 weeks. Subcutaneous administration uses a concentration of 100–200 g/L and an infusion volume limited by local tolerability. For intramuscular use, the protein concentration is adjusted to 150–180 g/L; intramuscular injection is not used for high-dose replacement because volume limits restrict total dose. Subvisible aggregate formation is accelerated by agitation and freeze-thaw cycling; liquid injectable formulations are protected by polysorbate 80 at ≤ 100 ppm, which reduces air-water interfacial stress but does not prevent pH-induced unfolding at pH < 4.5. Do not freeze the liquid injectable unless the container is validated for freeze-thaw; lyophilized injectable product should be reconstituted with sterile water for injection to a protein concentration of 50–100 g/L and used immediately.

Differences From Hyperimmune and Recombinant Immunoglobulin Preparations

Hyperimmune immunoglobulins are collected from donors with a defined high-titer antibody to a single antigen, such as anti-D or anti-hepatitis B, and are standardized by potency assays. Human normal immunoglobulin is not antigen-specific; it contains the polyclonal IgG repertoire of a pooled donor panel of not fewer than 1,000 individuals, giving a broad but donor-dependent antibody distribution. Recombinant monoclonal antibodies are produced in Chinese hamster ovary or NS0 cells and carry engineered single-specificity variable regions, whereas human normal immunoglobulin retains natural IgG subclass ratios and the native Fc glycan profile, including terminal galactose and fucose variants that influence complement-dependent cytotoxicity. Animal serum-derived immunoglobulins are not acceptable for repeated human use due to serum sickness and anti-animal antibody responses; human normal immunoglobulin removes those risks but does not eliminate human pathogen transmission, which is controlled by donor screening under 21 CFR 640.3 and Ph. Eur. 5.1.7 viral safety studies. Oral pharmaceutical-grade human normal immunoglobulin differs from food-grade colostrum-derived immunoglobulin powders in that the former is manufactured under drug GMP and does not use bovine or caprine milk fractions.

Avoid combination of the oral-grade powder with amine-based excipients in aqueous granulation, because elevated pH accelerates deamidation and aggregate formation. Do not mix injectable-grade liquid with solutions containing aluminum salts or polyvalent cations that can precipitate IgG; use dedicated infusion sets with 0.2 µm inline filters for intravenous administration. The oral grade is not interchangeable with injectable grade in clinical protocols; the oral product is not sterile and must not be administered by injection.